Updated Covid boosters offer 40-60% protection against illness, first real-world study shows

The first real-world test of the updated Covid-19 boosters has arrived, and the news is modest. The new shots, designed to target the Omicron subvariants currently spreading across the country, do offer protection against infection—somewhere in the range of 40 to 60 percent. But that protection is not what Americans saw when the original vaccines rolled out in 2020, when efficacy against symptomatic illness climbed above 90 percent. The gap between then and now tells a story about how the virus has evolved, and how our defenses against it have had to adapt.

The study, led by researchers at the CDC, examined health records from more than 360,000 Covid tests administered at nearly 10,000 retail pharmacies between mid-September and mid-November, when the BA.4 and BA.5 subvariants were driving most infections in the United States. The findings showed clear age-related patterns. Adults aged 18 to 49 who had received the bivalent boosters were 43 percent less likely to develop symptomatic infection compared to unvaccinated people. That protection fell sharply with age: those 50 to 64 saw a 28 percent reduction in risk, and those 65 and older experienced only a 22 percent reduction. The immune system's weakening with age, researchers noted, accounts for much of this difference.

Dr. Ruth Link-Gelles, an epidemiologist at the CDC, framed the results as a return to a familiar baseline. The original vaccines had delivered extraordinary protection in the pre-Delta era. Delta brought that down to around 70 percent. Omicron pushed it lower still, to roughly 50 percent. The new bivalent boosters, she explained, restore protection to approximately where previous boosters had landed—which is to say, not where we started, but where we've come to expect boosters to perform. The comparison to seasonal flu vaccines is instructive: over the past decade, flu vaccine effectiveness has ranged from 19 to 52 percent, depending on how well the vaccine strains match the circulating viruses. Covid boosters are now operating in that same territory.

Yet uptake has been sluggish. Only 11 percent of eligible Americans have received the updated boosters since they became available in early September. At a White House briefing, Dr. Anthony Fauci urged people to get the shot, calling the new data "really quite good" and framing vaccination as protection not just for oneself but for family and community. But the numbers suggest the message has not resonated widely. Link-Gelles acknowledged the limitation plainly: "This protection is not 100 percent, but it is something." She emphasized that as people prepare to travel and gather with elderly relatives during the holidays, even partial protection against infection carries weight—both for personal health and for avoiding transmission to vulnerable people.

The protection, however, is temporary. Peak effectiveness comes about a month after vaccination, then begins to decline. For those who were two to three months past their last vaccine dose, the bivalent boosters added roughly 30 percent additional protection for younger adults, with slightly higher gains for older age groups. By three months out, people 50 and older retained about 20 percent protection from the booster alone. Those who waited eight months or longer between doses saw larger gains—56 percent added protection for those 18 to 49—but Link-Gelles noted that by eight months, previous vaccine doses had offered little defense against Omicron, so the booster was essentially starting from scratch.

John Moore, an immunologist at Weill Cornell Medicine, distilled the takeaway: boosters will probably cut your risk of getting sick by about half, and that protection probably won't last. The implication is clear—this is not a permanent solution, but a temporary reinforcement that will need repeating.

The broader immunity picture in the United States has become intricate. According to CDC data, roughly two-thirds of Americans have completed at least their primary vaccine series. A new preprint study from Harvard and Yale researchers estimates that 94 percent of Americans have been infected with the virus at least once, and 97 percent have either been infected or vaccinated. That layered immunity—from shots, from prior infection, or from both—has pushed population-level protection against severe disease to around 89 percent as of November. The country is in a stronger defensive position than it has ever been, at least against the variants currently in circulation.

But Link-Gelles and other experts are careful not to declare victory. They recommend a layered approach: vaccination, yes, but also rapid tests, high-quality masks, and good ventilation. She described it as a toolbox, with vaccines as one essential tool among several. She noted that even though her own family is fully vaccinated, they plan to wear N95 masks when traveling to visit elderly relatives—a practical acknowledgment that no single measure offers complete protection, and that the most vulnerable people in our lives deserve multiple layers of defense.